Pharmacom Biovet Stock Performance
| PHMB Stock | USD 0.0001 0.00 0.00% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Pharmacom Biovet are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Pharmacom Biovet has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong primary indicators, Pharmacom Biovet is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:15 | Last Split Date 2008-09-10 |
Pharmacom | Build AI portfolio with Pharmacom Stock |
Pharmacom Biovet Relative Risk vs. Return Landscape
If you would invest 0.01 in Pharmacom Biovet on November 5, 2025 and sell it today you would earn a total of 0.00 from holding Pharmacom Biovet or generate 0.0% return on investment over 90 days. Pharmacom Biovet is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Pharmacom, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pharmacom Biovet Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pharmacom Biovet for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pharmacom Biovet can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Pharmacom Biovet generated a negative expected return over the last 90 days | |
| Pharmacom Biovet has some characteristics of a very speculative penny stock | |
| Pharmacom Biovet has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (556.18 K) with profit before overhead, payroll, taxes, and interest of 0. |
Pharmacom Biovet Fundamentals Growth
Pharmacom Stock prices reflect investors' perceptions of the future prospects and financial health of Pharmacom Biovet, and Pharmacom Biovet fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pharmacom Stock performance.
| Current Valuation | 1.08 M | ||||
| Net Income | (556.18 K) | ||||
| Total Debt | 61.54 K | ||||
| Total Asset | 112.36 K | ||||
| Retained Earnings | (19.05 M) | ||||
| Current Liabilities | 29 K | ||||
About Pharmacom Biovet Performance
By analyzing Pharmacom Biovet's fundamental ratios, stakeholders can gain valuable insights into Pharmacom Biovet's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pharmacom Biovet has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pharmacom Biovet has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
PharmaCom BioVet, Inc. focuses on operating a network of companion animal cancer treatment centers in the United States. PharmaCom BioVet, Inc. was incorporated in 1995 and is headquartered in Raleigh, North Carolina. PHARMACOM BIOVET operates under Medical Care Facilities classification in the United States and is traded on PNK Exchange.Things to note about Pharmacom Biovet performance evaluation
Checking the ongoing alerts about Pharmacom Biovet for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pharmacom Biovet help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharmacom Biovet generated a negative expected return over the last 90 days | |
| Pharmacom Biovet has some characteristics of a very speculative penny stock | |
| Pharmacom Biovet has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (556.18 K) with profit before overhead, payroll, taxes, and interest of 0. |
- Analyzing Pharmacom Biovet's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharmacom Biovet's stock is overvalued or undervalued compared to its peers.
- Examining Pharmacom Biovet's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharmacom Biovet's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharmacom Biovet's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharmacom Biovet's stock. These opinions can provide insight into Pharmacom Biovet's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pharmacom Stock analysis
When running Pharmacom Biovet's price analysis, check to measure Pharmacom Biovet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmacom Biovet is operating at the current time. Most of Pharmacom Biovet's value examination focuses on studying past and present price action to predict the probability of Pharmacom Biovet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmacom Biovet's price. Additionally, you may evaluate how the addition of Pharmacom Biovet to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |